CA125, the most well-established ovarian cancer biomarker, is known to be elevated in 50% of early-stage and 92% of advanced-stage ovarian cancers but has sensitivity issues, especially in the early stage of the disease [22]. This evidence concerns the gene MUC16 and ovarian cancer.